The US Food and Drug Administration (FDA) has proposed that manufacturers of biosimilar drugs seeking the agency’s interchangeable designation will no longer be required to perform switching studies. Current Biosimilar Interchangeability...
Research on positive symptoms of schizophrenia is well documented; however, cognitive, and negative symptoms of the illness have no approved therapies. Attaining clinical stability is of paramount importance. Nevertheless, outcomes...
Overview Health & Human Services announced on August 15 that the Center for Medicare and Medicaid Services (CMS) reached final agreements for new and lower drug prices for the initial ten...
CMS recently released proposed Contract Year 2025 Medicare payment rates for hospital outpatient and ambulatory surgical center sites of care. The 60-day comment period is now open, and interested parties...
On April 10, 2024, the Centers for Medicare & Medicaid Services (CMS) issued the fiscal year (FY) 2025 Medicare hospital inpatient prospective payment system (IPPS) and long-term care hospital prospective...
BluePath’s initial acquisition expands its product and service offerings in the biopharmaceutical commercialization services sector. BluePath Solutions, a Los Angeles based health economics and value communication consulting firm announced today that...
Patients diagnosed with cancer may face significant financial toxicity, specifically out-of-pocket (OOP) costs related to medical care. Diagnosis and treatment of cancer at earlier stages may reduce this burden. To...
In a recently published microcosting analysis using trial healthcare resource utilization data, our colleagues estimated post-infusion costs with the chimeric antigen receptor (CAR) T cell therapy, idecabtagene vicleucel (ide-cel),...
Allogeneic hematopoietic cell transplantation (allo-HCT) has the potential for curative outcomes in a variety of hematologic malignancies but are often associated with adverse events, specifically chronic graft versus host disease...
Our colleagues recently participated in one of the first large-scale claims analyses to date on estimating the time to diagnosis across a range of cancer types. The recent article, published...
